Abstract. While gastrointestinal (GI) hemorrhage is common in the general population, few studies have evaluated large numbers of GI hemorrhage patients with pancreatic cancer. The clinical features and potential risk factors of GI hemorrhage with pancreatic cancer was investigated in the present study and the effect of GI hemorrhage on survival rate was examined. Patients enrolled in the present study had pathologically proven pancreatic cancer, and received treatment between August 2006 and 2012. Their medical records were retrospectively reviewed. The data for the present study were obtained from a review of 246 patients with pancreatic cancer (average age, 63.4±10.92 years; 190 male cases, 56 female cases). In addition, 73 cases had stage I-II, 173 had stage III-IV, and only 67 cases (27.2%) were candidates for curative pancreatectomy. Among them, 32 cases (13.0%) were clinically diagnosed with GI hemorrhage. A total of 24 cases were male patients and the other 8 cases were female, the cases of hemorrhage history and alcoholism were 2 and 29 cases, respectively. The major initial clinical symptoms of GI hemorrhage included 18 patients with melena or blood stool (56.25%), 9 with haematemesis (28.13%), 3 with abdominal distention (9.37%) and 2 with stomach ache (6.25%). The independent risk factor for GI hemorrhage was tumor initial stage of IV. A continuous increase in carbohydrate antigen 19-9 (CA19-9) may be a warning of GI hemorrhage, particularly when it is >1,000 U/ml. The most frequent method of hemostasis was combination therapy (n=12, 37.5%). Only 3 cases (9.3%) of these 32 GI hemorrhage patients were blood stanched and only 10 patients (31.2%) received gastroscopy. The time from GI hemorrhage to fatality is extremely short (median 30 days, range from 1 h to 65 days), and the median overall survival time of the patients with GI hemorrhage was 9.0 months (range, 2.0-16.0 months) and was significantly shorter than that of patients without GI hemorrhage [14.5 months (range, 0.5-48.0 months)]. In conclusion, although GI hemorrhage was not common in patients with pancreatic cancer, it is critical. GI hemorrhage was controlled with endoscopic hemostasis. Clinicians should fully assess the risk factors of GI hemorrhage (such as alcohol, smoking, past hemorrhage history, initial stage, tumor location and CA19-9 level at diagnosis of pancreatic cancer) when the pancreatic cancer patients were on admission, particularly for patients of the late stage, preventive measures should be investigated to reduce suffering.
Introduction
Pancreatic cancer is the fourth leading cause of cancer-related fatalities in the USA with a 5-year survival rate of 4-6% (1,2). The only curative treatment for pancreatic cancer is surgical resection (3) . However, 25% of patients with pancreatic cancer are candidates for curative pancreatectomy. In recent years, chemoradiotherapy (CRT) has been considered as a reasonable treatment for locally advanced pancreatic cancer (LAPC). The main complications of pancreatic cancer include diabetes, thrombophlebitis, weight loss and mental symptoms, while GI hemorrhage with serious prognosis is so unusual that investigators seldom have the research and systematic exposition, leading to a long-term limit in the research in this field.
Gastrointestinal (GI) hemorrhage is caused by numerous different lesions and varies greatly in severity, ranging from clinically insignificant to life threatening (4) . It is a frequent cause of hospitalization, although a number of advances have been made in diagnosis and treatments. Studies from the United States indicated that hospitalizations for upper GI (UGI) hemorrhage in the early 1990s occurred at an annual incidence of ~100/100,000 population and were ~5 times more common than hospitalizations for lower GI hemorrhage (5) (6) (7) (8) (9) . UGI hemorrhage usually causes fatalities in 6-14% of those it affects (9, 10) . Patient morbidity and mortality is typically proportional to the degree of initial blood loss, the rate of rebleeding following endoscopy, underlying illnesses, and of note, the age of the patient age (10) (11) (12) (13) . A systematic study by Laine et al (14) suggested that the most common causes of UGI hemorrhage include peptic ulcer disease [32.1/100,000, (with gastric ulcers more than duodenal)], gastritis or duodenitis (10.0/100,000), angiodysplasia (5.02/100,000), esophageal ulcer (2.71/100,000), esophageal varices (1.25/100,000), Dieulafoy's lesion (1.26/100,000), gastrojejunal ulcer (1.49/100,000) and unspecified peptic ulcer (0.83/100,000). Abdominal arteriography may localize GI hemorrhage sources in approximately one-third of cases. Selective embolization may provide definitive hemostasis in the outcomes of the majority of instances of GI hemorrhage (15) . However, there are few studies on the rate and the risk factors of GI hemorrhage in patients with pancreatic cancer, which lead to an ambiguous GI hemorrhage rate of pancreatic cancer and controversy remains in the cause, treatment and outcome.
Therefore, the present study evaluated the incidence and survival time of the GI hemorrhage patients in pancreatic cancer in The First Affiliated Hospital of Liaoning Medical University (Jinzhou, China) over the past 6 years, to assess the clinical characteristics and to determine the risk factors for it. The study aimed to overcome the incomplete estimates of GI hemorrhage patients in pancreatic cancer in the previous studies. (16) or coagulopathy (coagulopathy was defined as a platelet count of 50,000/mm 3 , a prothrombin time/international normalized ratio of 1.5 or an activated partial thromboplastin time 2.03 the control value) were also excluded for the protocol analysis. The study was approved by the Ethics Committee of the First Affiliated Hospital of Liaoning Medical University.
Materials and methods

Patients
GI hemorrhage. GI hemorrhage was defined as any episode of fresh blood or coffee ground materials in nasogastric aspirate, hematemesis, melena or bloody stool. GI hemorrhage was considered severe if accompanied by hypotension (systolic blood pressure, 100 mmHg), a decrease in the hemoglobin (Hb) level of 2 g/dl or requiring blood transfusion (17) . In the study, to determine the risk factors for GI hemorrhage, the history of peptic ulcer, alcohol, smoking or hemorrhage were recorded. The treatment for GI hemorrhage includes endoscopic hemostasis, angiography, embolization and conservative care. The methods of endoscopic hemostasis were hypertonic saline-epinephrine injection, human plasmin thrombin injection, argon plasma coagulation or hemoclipping. Rebleeding was confined to episodes within 7 days after successful hemostasis therapy. 
Statistical analysis.
To investigate the baseline characteristics, the χ 2 test and Student's t-test were used. Categorical variables were analyzed by the χ 2 test and continuous variables were assessed by the Student's t-test. To evaluate the survival effect of GI hemorrhage, Cox regression test was used. The Kaplan-Meier method and the log-rank test were used to compare the survival rate between patients with and without GI hemorrhage. Univariate analysis and multivariate logistic regression were used to detect independent risk factors associated with hemorrhage for pancreatic cancer and prognosis. P<0.05 was considered to indicate a statistically significant difference. Analyses were performed using SPSS software, version 17.0 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics.
During the 6-year study period, 246 patients with pancreatic cancer were eligible for analysis (Table I ). The average age at the time of the diagnosis of pancreatic cancer was 63.4±10.92 years. Male patients accounted for 77.24% of the population, ~2 times more than females. A total of 3 patients suffered from a history of hemorrhage prior to the diagnosis of pancreatic cancer. The tumors were mostly located at the pancreatic head (57.72%). The most common symptom when diagnosed with pancreatic cancer is abdominal distension or pain (53.66%). The level of carbohydrate antigen 19-9 (CA19-9) was 549.1±967.1 U/ml. Surgery was performed for 67 patients (27.25%) and CRT was delivered to 77 patients (31.30%), with the specific dose determined according to the NCCN guidelines for pancreatic cancer (Fig. 1) . The median follow-up period was 14.6 months (range, 1.5-60.1 months).
GI hemorrhage. There were 32 patients (13.0%) who suffered from GI hemorrhage (Table II) . The initial Hb was 11.2±25.5 g/dl, which decreased to 8.4±17.1 g/dl when bleeding and the median CA19-9 level increased from 456.7±547.1 to 1,408.5±789.4. Among the total 32 GI hemorrhage patients, there were 7 patients belonging to the mild GI hemorrhage group with grade 1, 15 patients in the moderate GI hemorrhage group with grade 2 or 3 and 10 patients in the severe GI hemorrhage group with grade 4 or 5. Due to a bad physical state, conservative care was delivered to 11 cases and endoscopic hemostasis to 20 cases, while only 1 case underwent angiography and embolization. Prior to GI hemorrhage, surgical treatment was delivered to 5 patients (15.6%) and CRT was delivered to 25 patients (78.13%). The most common major initial clinical symptoms for GI hemorrhage were melena or blood stool and haematemesis. Due to a bad physical state, only 20 patients underwent UGI endoscopy. The results showed the cause of bleeding to be a gastric ulcer in 8 patients, duodenal ulcer in 5, radiation gastritis in 3 and another reason in 4. UGI endoscopy was not performed in 12 patients upon the rejection of their guardians or a bad physical state. As the patients were in terminal stages, the guardians did not want them to undergo any more examinations. Hemorrhage was successfully stopped by endoscopic treatment in 12 patients (37.5%). The methods of endoscopic hemostasis included hypertonic saline-epinephrine injection, argon plasma coagulation, human plasmin thrombin injection or hemoclipping. Embolization was performed in 1 patient and hemorrhage was finally stopped. However, 7 cases rebled and 18 patients in total succumbed to GI hemorrhage. The average time from GI hemorrhage to mortality was 31.5±21.6 days and the average overall survival rate was 10.0±6.2 months.
Risk factors for GI hemorrhage. The incidence of GI hemorrhage was 13.0 (n=32) and 10.2% (n=25) of patients succumbed due to bleeding. The present study analyzed the association between clinical parameters and the risk of GI hemorrhage.
In the univariate analysis, there was no statistically significant difference in gender, age, past ulcer history, past diabetes history, past cirrhosis history, the type of received treatment prior to hemorrhage, initial blood pressure, initial heart rates, Hb, platelet and international normalized ratio/partial thromboplastin time between the GI hemorrhage and the no-GI hemorrhage groups (Table III) (Table IV) . The hazard ratio was 1.246 (95% CI, 0.754-2.060) for the effects of GI hemorrhage on the survival rate, but it was not significant (Table V) . 
GI hemorrhage --------------------------------------------------------------------------------------------------------------------
Variables
Presence, n (%) P-value Survival. A total of 212 patients (86.2%) had succumbed at the time of final analysis. The median overall survival time was 9.0 months (range, 2.0-6.0 months) in patients without GI hemorrhage and 14.5 months (range, 0.5-48.0 months) in patients with GI hemorrhage (Fig. 2) , although the difference of the overall survival time was significant with P<0.05. The median period from clinically diagnosed GI hemorrhage to fatality was extremely short (30 days range from 1 h to 65 days).
Discussion
In certain cases, GI hemorrhage may be a symptom of a serious or life-threatening condition that should be immediately evaluated in an emergency setting. The present analysis showed that the median period from GI hemorrhage to mortality is extremely short for the patients with pancreatic cancer, and the median overall survival time of the patients with GI hemorrhage was significantly shorter than that of patients without GI hemorrhage, which was similar with other studies (18) (19) (20) , and is critical if not treated properly. The main treatment for GI hemorrhage in patients include fasting, proton pump inhibitor and endoscopic therapy, which may be effective to a certain degree, however, the effect to patients of GI hemorrhage with pancreatic cancer was not so clear, with an even shorten survival rate. The patients of pancreatic cancer are common in a significant tumor load state and their body condition is extremely poor, therefore, clinical doctors are usually unable to do anything. From this perspective, it is critical to early diagnose GI hemorrhage and to prevent it as soon as possible.
There are certain studies that are committed to the cause prevention and the treatment of GI hemorrhage, while there are few studies that focus on the early prevention, early diagnosis and the reasonable treatment of GI hemorrhage associated with pancreatic cancer. Regarding the risk factors for GI hemorrhage of pancreatic cancer, a study reported that the independent risk factor for GI hemorrhage was tumor location in the pancreatic body (21) . The patients enrolled in the present study received CRT for pathologically proven LAPC. However, there are few studies that reported the risk factors of all the stages of pancreatic cancer patients. In the present study, the initial clinical tumor stage of IV was one of the main factors (OR, 21.94, P=0.008). To a certain degree, the late stage of pancreatic cancer as the independent risk factor is understandable and it is likely associated with numerous factors, such as heavy tumor burden, complex treatment, poor physical fitness of patients and the larger mass may even increase the probability of violations of the digestive tract. Thus, more studies are required to investigate whether there is any difference between the different tumor stages or the different treatment.
The present study has several limitations. First, it was a retrospective study and a small number of patients were evaluated. Second, regarding the therapy of pancreatic cancer, the chemotherapy and pain management-induced adverse effects could not be excluded. In addition, the regimens were different between each other and the numbers of patients receiving gemcitabine differed from those receiving 5-FU, and several studies have reported that gemcitabine is more toxic than 5-FU (22, 23) . Third is hospital stay and blood transfusion, which were evaluated in other studies (24, 25) . Therefore, further studies are required to improve the outcomes in GI hemorrhage patients with pancreatic cancer.
In conclusion, the present results show that GI hemorrhage is critical in pancreatic cancer patients. Not only was the median overall survival rate of the patients with GI hemorrhage significantly shorter than that of patients without GI hemorrhage, but the time from GI hemorrhage to mortality was also extremely short. Clinical oncologists should pay more attention to those who had a late stage of pancreatic cancer. The clinicians should consider GI hemorrhage in pancreatic cancer patients. Extensive studies are required to explore more effective treatment measures. 
